HomeProductsBioactive CompoundsNeuronal SignalingAChRImidafenacin
Chemical structure of CAS 170105-16-5

Imidafenacin

In Stock•Starting at $67 for 100 mg•Purity ≥ 98%
CAS No.170105-16-5
MDL No.MFCD09833703
MFC20H21N3O
MW319.40
InChI KeySQKXYSGRELMAAU-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
100 mg98%$67In Stock
250 mg98%$83In Stock
1 g98%$99In Stock
5 g98%$484In Stock
10 g98%$771In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Imidafenacin is a diarylmethane compound.

CAS No.170105-16-5
Product NameImidafenacin

Biological Targets

CHRM3

Associated Conditions

Urinary incontinence·overactive bladder·Polyuria
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 35, Issue 9 • 2007
PMID: 17567733DOI: 10.1124/dmd.107.016030

Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences • Vol. 853, Issue 1-2 • 2007
PMID: 17387045DOI: 10.1016/j.jchromb.2007.02.047

Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.

Arzneimittel-Forschung • Vol. 57, Issue 2 • 2007
PMID: 17396619DOI: 10.1055/s-0031-1296589

Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.

Arzneimittel-Forschung • Vol. 57, Issue 3 • 2007
PMID: 17469649DOI: 10.1055/s-0031-1296598

Documentation

Similar Products